Isoniazid News and Research

RSS

Patient adherence an essential factor for successful tuberculosis treatment

Nearly 2 million people die from tuberculosis each year, mainly in the poorest countries. The pathogen, Koch's bacillus, can pass easily by aerial infection from one individual to another. The spread of the disease, favoured by the Aids epidemic and the appearance of multi-resistant strains, has led WHO to make tuberculosis control one of the world's main health priorities.

27 Mar 2007

WHO adds four anti-tuberculosis medicines to its list of prequalified medicines

The World Health Organization (WHO) has added four anti-tuberculosis medicines to its list of prequalified products.

25 Mar 2007

U.S. tuberculosis rates all-time low in 2006

Drug-resistant TB, including extensively drug-resistant TB, presents significant challenges to treatment and control of the disease in the United States and abroad, according to articles in today's "Morbidity and Mortality Weekly Report" (MMWR).

22 Mar 2007

Majority of South Africans with HIV have drug resistant TB

Researchers at a conference in Los Angeles have said that as many as 85% of HIV-positive South Africans are also infected with an extensively drug-resistant form of tuberculosis (TB), Extensive Drug Resistant TB (XDR-TB).

27 Feb 2007

XDR-TB in South Africa

A team of medical ethics and public health experts say tough isolation measures, involuntary if need be, are justified to contain a deadly, contagious, drug-resistant strain of TB in South Africa and to prevent "a potentially explosive international health crisis."

23 Jan 2007

Sequella receives FDA fast track status for pulmonary tuberculosis drug

Sequella, Inc. has announced it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for SQ109, the company's proprietary lead drug candidate for treatment of pulmonary tuberculosis (TB).

22 Jan 2007

TB drug isoniazid could reduce AIDS-related illnesses among children

The inexpensive tuberculosis drug isoniazid could help reduce by half the number of deaths from AIDS-related illnesses among children, according to a study published earlier this month in BMJ, the Pretoria News reports.

23 Nov 2006

Measures to combat XDR-TB worldwide

Health experts have confirmed that the emergence of extensively drug-resistant tuberculosis (XDR-TB) poses a serious threat to public health, particularly when associated with HIV.

17 Oct 2006

Extensive Drug Resistant TB now a major threat

The World Health Organization (WHO) has expressed concern over the emergence of virulent drug-resistant strains of tuberculosis (TB) and is calling for measures to be strengthened and implemented to prevent the global spread of the deadly TB strains.

5 Sep 2006

New antibiotic works against superbugs

A new antibiotic with the ability to fight drug-resistant superbugs has been developed by researchers at drug company Merck's research laboratories in New Jersey.

21 May 2006

Treating populations infected with both HIV and latent TB could speed the emergence of drug-resistant TB

In 2005, 46 regional Ministers of Health in Africa declared that a dramatic rise in tuberculosis (TB) cases was cause for emergency.

19 Apr 2006

Researchers find compound 10 times more effective than isoniazid, the leading anti-tuberculosis drug

Researchers at the Albert Einstein College of Medicine of Yeshiva University have synthesized chemicals that are up to 10 times more effective than isoniazid, the leading anti-tuberculosis drug.

28 Mar 2006

The incidence, distribution, and control of tuberculosis

A reduction in tuberculosis (TB) incidence, prevalence and death rate can be achieved by 2015 in most parts of the world, with the greatest challenges occurring in Africa and Eastern Europe, according to a projection by the Stop TB Department of the World Health Organization.

1 Mar 2006

Potential new drug for treating all forms of tuberculosis

An experimental tuberculosis drug may be effective against not only multi drug-resistant forms of the disease but could also be the first compound to treat the latent stage of infection as well. Researchers reported their results at the 2006 ASM Biodefense Research Meeting.

20 Feb 2006

New combination treatment that could dramatically shorten the length of tuberculosis treatment

The clinical results of a new combination treatment that could dramatically shorten the length of tuberculosis treatment were presented at a recent scientific conference in the USA. This virulent disease of the lungs still infects millions every year, with a notable resurgence in Europe, especially in the East.

10 Jan 2006

Promising new tuberculosis drug enters clinical trial

A promising new drug candidate that may be effective against both actively dividing and slow-growing Mycobacterium tuberculosis (M. tb) has begun testing in humans, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, announced this week.

15 Jun 2005

Non-profit public-private partnership develops affordable, new drug regimens for tuberculosis

The Global Alliance for TB Drug Development (TB Alliance), a non-profit public-private partnership developing affordable, new drug regimens for tuberculosis, today announced the start of Phase I clinical trials for the lead TB drug in its pipeline, PA-824. The trials begin this month.

14 Jun 2005